Ibio Inc (IBIO)

$0.78 +0.04 (5.88%)
Market Cap 12.24M
Revenue (ttm) 230,000.00
Net Income (ttm) -24.91M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -10,830.43%
Debt to Equity Ratio 0.07
Volume 1,071,559
Avg Vol 2,974,552
Day's Range N/A - N/A
Shares Out 16.52M
Stochastic %K 17%
Beta 0.94
Analysts Strong Sell
Price Target $4.30

Company Profile

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the...

Industry: Biotechnology
Sector: Healthcare
Phone: 979 446 0027
Website: ibioinc.com
Address:
11750 Sorrento Valley Road, Suite 200, San Diego, United States
Rower5oh
Rower5oh Jul. 7 at 9:06 PM
$IBIO LFG, Martin!
1 · Reply
Napoliblue
Napoliblue Jul. 7 at 4:21 PM
$IBIO spike coming offers are with size being swept next spike to $6 coming new partnership is huge
1 · Reply
MandM_Car2025
MandM_Car2025 Jul. 7 at 4:21 PM
$IBIO news has got to be coming out if it’s going up like it is
1 · Reply
2pumps1dump
2pumps1dump Jul. 7 at 4:20 PM
$IBIO
0 · Reply
HillBillyFarmer
HillBillyFarmer Jul. 7 at 4:11 PM
$IBIO Whos buying this worthless junk at these prices? Do an Offering and send this POS where it belongs.
1 · Reply
Joelew22
Joelew22 Jul. 7 at 3:56 PM
$IBIO potential milestones, both pipelines, and the tech should value this company at? My opinion is currently undervalued.
1 · Reply
Stokwits
Stokwits Jul. 7 at 3:55 PM
$IBIO I was just about to buy at 71 and it jumps to 73.
1 · Reply
Slypher
Slypher Jul. 7 at 3:15 PM
$IBIO just wait until we get some good news. $MBIO floating at 360% so far
0 · Reply
MandM_Car2025
MandM_Car2025 Jul. 7 at 3:14 PM
$IBIO all this needs to do is push to $1 let’s do it cmon
0 · Reply
Flo92
Flo92 Jul. 7 at 3:14 PM
$IBIO here we go 🚀🚀
0 · Reply
Latest News on IBIO
iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

Jun 24, 2025, 7:00 AM EDT - 13 days ago

iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

Jun 23, 2025, 4:15 PM EDT - 14 days ago

iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

Jun 16, 2025, 7:00 AM EDT - 21 days ago

iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

May 5, 2025, 8:00 AM EDT - 2 months ago

iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

iBio Reports Fiscal Third Quarter 2025 Financial Results

May 2, 2025, 8:00 AM EDT - 2 months ago

iBio Reports Fiscal Third Quarter 2025 Financial Results

iBio Raises $6.2 Million Through Warrant Inducement Transaction

Apr 29, 2025, 1:43 PM EDT - 2 months ago

iBio Raises $6.2 Million Through Warrant Inducement Transaction

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

Apr 22, 2025, 8:00 AM EDT - 2 months ago

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

Apr 7, 2025, 7:00 AM EDT - 3 months ago

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

iBio to Begin Trading on the Nasdaq Stock Exchange

Feb 19, 2025, 4:05 PM EST - 4 months ago

iBio to Begin Trading on the Nasdaq Stock Exchange

iBio Reports Fiscal Second Quarter 2025 Financial Results

Feb 10, 2025, 4:05 PM EST - 5 months ago

iBio Reports Fiscal Second Quarter 2025 Financial Results

iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio

Jan 2, 2025, 7:00 AM EST - 6 months ago

iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio

iBio Reports Fiscal First Quarter 2025 Financial Results

Nov 12, 2024, 4:05 PM EST - 8 months ago

iBio Reports Fiscal First Quarter 2025 Financial Results

iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Sep 20, 2024, 4:05 PM EDT - 10 months ago

iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

iBio to Participate in Upcoming Investor Conferences

Sep 3, 2024, 7:00 AM EDT - 10 months ago

iBio to Participate in Upcoming Investor Conferences

iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development

Aug 12, 2024, 4:30 PM EDT - 11 months ago

iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development

iBio Closes Sale of Manufacturing Facility in Texas

Jun 3, 2024, 7:00 AM EDT - 1 year ago

iBio Closes Sale of Manufacturing Facility in Texas

iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

May 13, 2024, 4:05 PM EDT - 1 year ago

iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

iBio stock nearly tripled on Wednesday: here's why

Mar 27, 2024, 2:43 PM EDT - 1 year ago

iBio stock nearly tripled on Wednesday: here's why

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

Mar 27, 2024, 7:00 AM EDT - 1 year ago

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

iBio Announces $15.0 Million Private Placement

Mar 26, 2024, 7:35 PM EDT - 1 year ago

iBio Announces $15.0 Million Private Placement

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka

Feb 26, 2024, 7:45 AM EST - 1 year ago

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka

iBio Announces Participation in 23rd Annual PepTalk Conference

Jan 16, 2024, 8:15 AM EST - 1 year ago

iBio Announces Participation in 23rd Annual PepTalk Conference

Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)

Jan 16, 2024, 6:50 AM EST - 1 year ago

Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)

ALVR GRI VYNE

iBio Amends and Extends Maturity of Credit Agreement

Dec 26, 2023, 7:15 AM EST - 1 year ago

iBio Amends and Extends Maturity of Credit Agreement

iBio, Inc. Announces Pricing of $4.5 Million Public Offering

Dec 5, 2023, 8:00 AM EST - 1 year ago

iBio, Inc. Announces Pricing of $4.5 Million Public Offering

iBio Announces Reverse Stock Split

Nov 27, 2023, 5:20 PM EST - 1 year ago

iBio Announces Reverse Stock Split

iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific

Nov 1, 2023, 8:24 AM EDT - 1 year ago

iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific

iBio Explains Recent Filing of Registration Statement

Oct 2, 2023, 6:45 AM EDT - 1 year ago

iBio Explains Recent Filing of Registration Statement

iBio Announces Filing of 2023 Annual Report on SEC Form 10-K

Sep 27, 2023, 4:19 PM EDT - 1 year ago

iBio Announces Filing of 2023 Annual Report on SEC Form 10-K

iBio Announces Amendment to Credit Agreement with Woodforest

Sep 21, 2023, 4:05 PM EDT - 1 year ago

iBio Announces Amendment to Credit Agreement with Woodforest

iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development

Aug 14, 2023, 4:15 PM EDT - 2 years ago

iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development

iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company's Next Stage of Growth

Jun 27, 2023, 8:00 AM EDT - 2 years ago

iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company's Next Stage of Growth

iBio Forges Research Collaboration with the National Institutes of Health

Jun 12, 2023, 4:15 PM EDT - 2 years ago

iBio Forges Research Collaboration with the National Institutes of Health

iBio to Participate in the JMP Securities Life Sciences Conference

May 9, 2023, 4:30 PM EDT - 2 years ago

iBio to Participate in the JMP Securities Life Sciences Conference

iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform

Apr 4, 2023, 4:05 PM EDT - 2 years ago

iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform

iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing

Mar 31, 2023, 8:10 AM EDT - 2 years ago

iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing

iBio Announces MUC16 as its Latest Immune-Oncology Target Program

Feb 16, 2023, 4:48 PM EST - 2 years ago

iBio Announces MUC16 as its Latest Immune-Oncology Target Program

iBio Announces Closing of $3.5 Million Underwritten Public Offering

Dec 9, 2022, 4:05 PM EST - 2 years ago

iBio Announces Closing of $3.5 Million Underwritten Public Offering

iBio Announces Pricing of $3.5 Million Underwritten Public Offering

Dec 6, 2022, 11:27 PM EST - 2 years ago

iBio Announces Pricing of $3.5 Million Underwritten Public Offering

iBio Announces Proposed Underwritten Public Offering

Dec 6, 2022, 4:01 PM EST - 2 years ago

iBio Announces Proposed Underwritten Public Offering

iBio® to Showcase the RubrYc® Discovery Engine During Poster Presentations at Antibody Engineering & Therapeutics Conference 2022

Dec 5, 2022, 8:00 AM EST - 2 years ago

iBio® to Showcase the RubrYc® Discovery Engine During Poster Presentations at Antibody Engineering & Therapeutics Conference 2022

iBio Announces CEO Departure

Dec 2, 2022, 4:30 PM EST - 2 years ago

iBio Announces CEO Departure

iBio, Inc. (IBIO) Q4 2022 Results - Earnings Call Transcript

Sep 27, 2022, 10:33 PM EDT - 3 years ago

iBio, Inc. (IBIO) Q4 2022 Results - Earnings Call Transcript

iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update

Sep 27, 2022, 4:10 PM EDT - 3 years ago

iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update

iBio Acquires RubrYc Therapeutics' AI Drug Discovery Platform and Pipeline

Sep 21, 2022, 8:30 AM EDT - 3 years ago

iBio Acquires RubrYc Therapeutics' AI Drug Discovery Platform and Pipeline

iBio, Inc. (IBIO) CEO Tom Isett on Q3 2022 Results - Earnings Call Transcript

May 12, 2022, 9:19 PM EDT - 3 years ago

iBio, Inc. (IBIO) CEO Tom Isett on Q3 2022 Results - Earnings Call Transcript

iBio Reports Fiscal Third Quarter 2022 Financial Results and Provides Corporate Update

May 12, 2022, 4:05 PM EDT - 3 years ago

iBio Reports Fiscal Third Quarter 2022 Financial Results and Provides Corporate Update

iBio to Report Fiscal 2022 Third Quarter Financial Results and Provide Corporate Update on Thursday, May 12, 2022

May 5, 2022, 4:30 PM EDT - 3 years ago

iBio to Report Fiscal 2022 Third Quarter Financial Results and Provide Corporate Update on Thursday, May 12, 2022

iBio to Participate in the Oppenheimer 32nd Annual Healthcare Conference

Mar 11, 2022, 8:00 AM EST - 3 years ago

iBio to Participate in the Oppenheimer 32nd Annual Healthcare Conference

iBio, Inc. (IBIO) CEO Tom Isett on Q2 2022 Results - Earnings Call Transcript

Feb 14, 2022, 10:40 PM EST - 3 years ago

iBio, Inc. (IBIO) CEO Tom Isett on Q2 2022 Results - Earnings Call Transcript

Rower5oh
Rower5oh Jul. 7 at 9:06 PM
$IBIO LFG, Martin!
1 · Reply
Napoliblue
Napoliblue Jul. 7 at 4:21 PM
$IBIO spike coming offers are with size being swept next spike to $6 coming new partnership is huge
1 · Reply
MandM_Car2025
MandM_Car2025 Jul. 7 at 4:21 PM
$IBIO news has got to be coming out if it’s going up like it is
1 · Reply
2pumps1dump
2pumps1dump Jul. 7 at 4:20 PM
$IBIO
0 · Reply
HillBillyFarmer
HillBillyFarmer Jul. 7 at 4:11 PM
$IBIO Whos buying this worthless junk at these prices? Do an Offering and send this POS where it belongs.
1 · Reply
Joelew22
Joelew22 Jul. 7 at 3:56 PM
$IBIO potential milestones, both pipelines, and the tech should value this company at? My opinion is currently undervalued.
1 · Reply
Stokwits
Stokwits Jul. 7 at 3:55 PM
$IBIO I was just about to buy at 71 and it jumps to 73.
1 · Reply
Slypher
Slypher Jul. 7 at 3:15 PM
$IBIO just wait until we get some good news. $MBIO floating at 360% so far
0 · Reply
MandM_Car2025
MandM_Car2025 Jul. 7 at 3:14 PM
$IBIO all this needs to do is push to $1 let’s do it cmon
0 · Reply
Flo92
Flo92 Jul. 7 at 3:14 PM
$IBIO here we go 🚀🚀
0 · Reply
Stokwits
Stokwits Jul. 7 at 3:13 PM
$IBIO Quiet board as price rises.
0 · Reply
Green_dillo
Green_dillo Jul. 7 at 3:08 PM
$IBIO watching
0 · Reply
RDMoneylover
RDMoneylover Jul. 7 at 1:32 PM
$IBIO show me some big spikes, my average is$25
1 · Reply
skitime
skitime Jul. 6 at 7:29 PM
$IBIO 🤷‍♂️
1 · Reply
MandM_Car2025
MandM_Car2025 Jul. 4 at 10:14 PM
$IBIO for the love of god we need news this week or something that can get this back to $1. Please we need a big buyer to skyrocket this to $1 so I can leave
1 · Reply
Rustie
Rustie Jul. 3 at 6:06 PM
$IBIO Happy Independence Day!! Have a great weekend everyone$$!!!
0 · Reply
Rower5oh
Rower5oh Jul. 3 at 12:21 PM
$IBIO Get it done, Martin!
0 · Reply
Wishn
Wishn Jul. 2 at 3:22 PM
$IBIO need a squeeze
2 · Reply
LambosOrrrrFoooodstamps
LambosOrrrrFoooodstamps Jul. 2 at 2:00 PM
$IBIO whats going on here i havent been around for a while? Any new happenings? Reverse splits? News? Might be time to swing a pump
0 · Reply
WZMAN7227
WZMAN7227 Jul. 1 at 4:52 PM
$IBIO average $37.46
1 · Reply
Joelew22
Joelew22 Jul. 1 at 4:31 PM
$IBIO watching availability and borrow rate. Not an expert but something seems off
1 · Reply
nonamestockz
nonamestockz Jul. 1 at 3:36 PM
$MBIO Gimme the short squeeze $CRKN $IVP $IBIO and many more
1 · Reply